BioProcess International

Regulatory Frameworks for Central Nervous System Safety Assessment: Bridging Traditional Methods and New Modalities

Despite new methodologies and flexible regulatory pathways, CNS biopharmaceuticals still face significant safety assessment ...
The American Journal of Managed Care

CNS-Directed AAV Gene Therapy: Immune Dynamics and Clinical Implications

CNS-directed AAV gene therapy shows milder immune responses compared to systemic administration, reducing peripheral immune activation and systemic toxicities. Direct CNS delivery can bypass ...

Chinese Neurosurgical Journal Study Explores Diagnostic Role of Brain Biopsy in Leukemia with CNS Involvement

Researchers analyzed the diagnostic value of stereotactic brain biopsy in patients with leukemia presenting central ...
Morningstar

Cumulus Neuroscience Presents Data at the International Society for CNS Clinical Trials and Methodology Autumn Conference and the 38th European College of ...

BELFAST, Northern Ireland, Oct. 13, 2025 /PRNewswire/ -- Cumulus Neuroscience (Cumulus; The Company), a global digital health company focused on advancing neuroscience clinical trials and patient care ...
Business Wire

Seaport Therapeutics Presents New Meta-Analysis Examining Correlations Between Clinical Trial Design Factors and Placebo Response in Major Depressive Disorder Studies

BOSTON--(BUSINESS WIRE)--Seaport Therapeutics (“Seaport” or the “Company”), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and ...
Nasdaq

Nurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies

SAN FRANCISCO, April 09, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat ...